{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T11:35:36.047948+00:00","company":{"ticker":"STRO","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC."},"pagination":{"limit":100,"returned":41,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Vaxcyte, Inc.","detail":"license","count":2,"first_seen":"2022-12-20T23:59:59+00:00","last_seen":"2023-11-27T23:59:59+00:00","evidence_fact_ids":[91390,189966]},{"display_name":"BofA Securities, Inc.","detail":"underwriting","count":1,"first_seen":"2024-04-02T23:59:59+00:00","last_seen":"2024-04-02T23:59:59+00:00","evidence_fact_ids":[63509]},{"display_name":"Ipsen Biopharmaceuticals, Inc.","detail":"equity_purchase","count":1,"first_seen":"2024-04-02T23:59:59+00:00","last_seen":"2024-04-02T23:59:59+00:00","evidence_fact_ids":[63515]},{"display_name":"Ipsen Pharma SAS","detail":"license","count":1,"first_seen":"2024-04-02T23:59:59+00:00","last_seen":"2024-04-02T23:59:59+00:00","evidence_fact_ids":[63514]},{"display_name":"Jefferies LLC","detail":"atm_program","count":1,"first_seen":"2026-03-23T23:59:59+00:00","last_seen":"2026-03-23T23:59:59+00:00","evidence_fact_ids":[27744]},{"display_name":"Leerink Partners LLC and TD Securities LLC","detail":"underwriting","count":1,"first_seen":"2026-02-10T23:59:59+00:00","last_seen":"2026-02-10T23:59:59+00:00","evidence_fact_ids":[32974]},{"display_name":"affiliate of Blackstone Life Sciences","detail":"asset_purchase","count":1,"first_seen":"2023-06-26T23:59:59+00:00","last_seen":"2023-06-26T23:59:59+00:00","evidence_fact_ids":[135385]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"f8372c6818c0cf54ec8e9602905bbdecd1c25cc4","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-06-08T20:01:05+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-05","outcome":"passed","proposal_text":"Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,540,863","subject":null,"votes_abstain":"6,452","votes_against":"22,412","votes_for":"11,329,946","votes_withheld":null}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting at the 2026-06-05 meeting.","evidence_excerpt":"3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting: Shares For Shares Against Shares Abstaining Broker Non-Votes 11,329,946 22,412 6,452 2,540,863","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-261658","anchor_url":"https://secwatch.observer/filing/0001193125-26-261658#claim-f8372c6818c0cf54ec8e9602905bbdecd1c25cc4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm"},{"fact_type":"shareholder_vote","fact_key":"deddecf3a09000d0694e35f4fd645f8d98b55a64","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-06-08T20:01:05+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-05","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"5,883","votes_against":"501","votes_for":"13,893,289","votes_withheld":null}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.","evidence_excerpt":"2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Abstaining 13,893,289 501 5,883","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-261658","anchor_url":"https://secwatch.observer/filing/0001193125-26-261658#claim-deddecf3a09000d0694e35f4fd645f8d98b55a64","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cd9f02979ac0d60ed21a171edaf1753465e650d3","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-06-08T20:01:05+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-05","outcome":"passed","proposal_text":"Election of three Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,540,863","subject":"Jane Chung","votes_abstain":null,"votes_against":null,"votes_for":"11,355,214","votes_withheld":"3,596"},{"broker_non_votes":"2,540,863","subject":"Connie Matsui","votes_abstain":null,"votes_against":null,"votes_for":"9,734,802","votes_withheld":"1,624,008"},{"broker_non_votes":"2,540,863","subject":"James Panek","votes_abstain":null,"votes_against":null,"votes_for":"9,706,422","votes_withheld":"1,652,388"}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2026-06-05 meeting.","evidence_excerpt":"On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”), and the following proposals were adopted: 1. Election of three Class II directors","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-261658","anchor_url":"https://secwatch.observer/filing/0001193125-26-261658#claim-cd9f02979ac0d60ed21a171edaf1753465e650d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/0001193125-26-261658-index.htm"},{"fact_type":"earnings_release","fact_key":"64eecd96dc939fbfa89200331054d221c59f4ba5","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-05-14T20:15:18+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter of 2026","report_date":"2026-05-14","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the first quarter of 2026.","evidence_excerpt":"Sutro Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-26-224065","anchor_url":"https://secwatch.observer/filing/0001193125-26-224065#claim-64eecd96dc939fbfa89200331054d221c59f4ba5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/0001193125-26-224065-index.htm"},{"fact_type":"earnings_release","fact_key":"4797d55ebdb8cde9b52213afd25674b6ae568e73","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year 2025","report_date":"2026-03-23","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the full year 2025.","evidence_excerpt":"On March 23, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001193125-26-119844","anchor_url":"https://secwatch.observer/filing/0001193125-26-119844#claim-4797d55ebdb8cde9b52213afd25674b6ae568e73","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/0001193125-26-119844-index.htm"},{"fact_type":"material_agreement","fact_key":"89de926e34215f7aa3f736f89ea928072f9d407d","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Sales Agreement","agreement_type":"atm_program","counterparty":"Jefferies LLC","effective_date":"2026-03-23","item_codes_triggered":["1.02"],"value_text":null},"claim":"SUTRO BIOPHARMA, INC. terminated Sales Agreement with Jefferies LLC (effective 2026-03-23).","evidence_excerpt":"On March 23, 2026, the Company and Agent mutually agreed to terminate the Sales Agreement effective immediately as of March 23, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-119844","anchor_url":"https://secwatch.observer/filing/0001193125-26-119844#claim-89de926e34215f7aa3f736f89ea928072f9d407d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/0001193125-26-119844-index.htm"},{"fact_type":"material_agreement","fact_key":"59cc37a5609caa24dcc5507c90ec3668c935cd36","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2026-02-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein","effective_date":"2026-02-09","item_codes_triggered":["1.01"],"value_text":"approximately $110.0 million"},"claim":"SUTRO BIOPHARMA, INC. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein valued at approximately $110.0 million (effective 2026-02-09).","evidence_excerpt":"On February 9, 2026, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-044934","anchor_url":"https://secwatch.observer/filing/0001193125-26-044934#claim-59cc37a5609caa24dcc5507c90ec3668c935cd36","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526044934/0001193125-26-044934-index.htm"},{"fact_type":"governance_change","fact_key":"c97633e2d655290243ebaf40cfadc0420c33dba3","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-12-03T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-03","item_codes_triggered":["5.03"],"summary_text":"Amendment to Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split"},"claim":"SUTRO BIOPHARMA, INC.: Amendment to Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split (effective 2025-12-03).","evidence_excerpt":"On December 2, 2025, Sutro Biopharma, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Amendment ”) to its Restated Certificate of Incorporation (the “ Certificate of Incorporation ”) with the Secretary of State of the State of Delaware to implement a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) to be effective as of 12:01 am Eastern time on December 3, 2025 (the “ Effective Time ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-306786","anchor_url":"https://secwatch.observer/filing/0001193125-25-306786#claim-c97633e2d655290243ebaf40cfadc0420c33dba3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525306786/0001193125-25-306786-index.htm"},{"fact_type":"restructuring_charge","fact_key":"e2a8a4c0528a73c264233586727deebc4c6b4951","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-09-29T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $4.1million to $4.3 million","effective_date":"2025-09-29","event_type":"restructuring","headcount_text":"approximately one-third","item_codes_triggered":["2.05"]},"claim":"SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $4.1million to $4.3 million (approximately one-third).","evidence_excerpt":"As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-223434","anchor_url":"https://secwatch.observer/filing/0001193125-25-223434#claim-e2a8a4c0528a73c264233586727deebc4c6b4951","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/0001193125-25-223434-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"87473a067640e232eaef286f94a5485d0441b14c","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-06-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-12-17","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-06-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Listing Rule 5450(a)(1) and Listing Rule 5810(c)(3)(A)","reported_value":null,"rule_numbers":["5450(a)(1)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"SUTRO BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"June 20, 2025, Sutro Biopharma, Inc. (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until December 17, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-089978","anchor_url":"https://secwatch.observer/filing/0000950170-25-089978#claim-87473a067640e232eaef286f94a5485d0441b14c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025089978/0000950170-25-089978-index.htm"},{"fact_type":"executive_change","fact_key":"a3a5ce195f","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-06-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-02","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Gregory K. Chow was appointed as Chief Financial Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-133268","anchor_url":"https://secwatch.observer/filing/0001193125-25-133268#claim-a3a5ce195f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525133268/0001193125-25-133268-index.htm"},{"fact_type":"executive_change","fact_key":"ca694f45e8","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-04-14T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-06","interim":false,"role":null,"role_category":"director","successor_name":null,"successor_named":false},"claim":"John Freund departed as director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"John Freund, M.D., a member of the Board of Directors (the “Board”) of Sutro Biopharma, Inc., a Delaware corporation (the “Company”) since 2014, informed the Board of his decision to not stand for re-election to the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-053733","anchor_url":"https://secwatch.observer/filing/0000950170-25-053733#claim-ca694f45e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025053733/0000950170-25-053733-index.htm"},{"fact_type":"restructuring_charge","fact_key":"5f8d9655f2dcf56c02ce5894aa5a919fcd76cde8","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"affected_area":"luveltamab tazevibulin (luvelta) activities and internal GMP manufacturing facility","charge_text":"approximately $40 million to $45 million","effective_date":"2025-03-13","event_type":"restructuring","headcount_text":"approximately 50%","item_codes_triggered":["2.05"]},"claim":"SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $40 million to $45 million affecting luveltamab tazevibulin (luvelta) activities and internal GMP manufacturing facility (approximately 50%).","evidence_excerpt":"The total cash payments and costs related to deprioritizing luvelta-related activities and reducing the workforce are estimated to be approximately $40 million to $45 million, with a significant majority of these amounts expected to be paid in 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-25-038879","anchor_url":"https://secwatch.observer/filing/0000950170-25-038879#claim-5f8d9655f2dcf56c02ce5894aa5a919fcd76cde8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm"},{"fact_type":"executive_change","fact_key":"bc7be10884","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-13","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jane Chung was appointed as Class II Director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"The Board also appointed Ms. Chung as a Class II Director of the Company, effective as of the Newell Separation Date.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-25-038879","anchor_url":"https://secwatch.observer/filing/0000950170-25-038879#claim-bc7be10884","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm"},{"fact_type":"executive_change","fact_key":"e270a82861","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-13","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Jane Chung was appointed as Chief Executive Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"Effective as of the Newell Separation Date, the Board appointed Jane Chung, the Company’s President and Chief Operating Officer, to succeed Mr. Newell as Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-25-038879","anchor_url":"https://secwatch.observer/filing/0000950170-25-038879#claim-e270a82861","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm"},{"fact_type":"executive_change","fact_key":"00d45bcfc9","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"William J. Newell resigned as Director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"resigned as a director of the Board, effective as of the Newell Separation Date","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-25-038879","anchor_url":"https://secwatch.observer/filing/0000950170-25-038879#claim-00d45bcfc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm"},{"fact_type":"executive_change","fact_key":"87056b342b","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-13","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Jane Chung","successor_named":true},"claim":"William J. Newell resigned as President and Chief Executive Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"Mr. Newell ceased his role as the Company’s President and CEO, effective March 13, 2025","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-25-038879","anchor_url":"https://secwatch.observer/filing/0000950170-25-038879#claim-87056b342b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/0000950170-25-038879-index.htm"},{"fact_type":"executive_change","fact_key":"edf583a552","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-08-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sukhi Jagpal was appointed as Director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On August 8, 2024, the board of directors (the “ Board ”) of Sutro Biopharma, Inc. (the “ Company ”) appointed Sukhi Jagpal, as a Class III director, effective as of August 8, 2024, and as a member of the Audit Committee, effective as of August 15, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-095486","anchor_url":"https://secwatch.observer/filing/0000950170-24-095486#claim-edf583a552","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024095486/0000950170-24-095486-index.htm"},{"fact_type":"earnings_release","fact_key":"1b42e4e68c0967c92f27df1c386838d4b13c66a2","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$267.6 million","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":"$13.0 million"},"claim":"SUTRO BIOPHARMA, INC. reported the quarter ended March 31, 2024 results: revenue $13.0 million, net income $267.6 million.","evidence_excerpt":"stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $13.0 million for the quarter ended March 31, 2024, as compared to $12.7 million for the same period in 2023, with the 2024 amount related principally to the Astellas collaboration, and the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-058701","anchor_url":"https://secwatch.observer/filing/0000950170-24-058701#claim-1b42e4e68c0967c92f27df1c386838d4b13c66a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024058701/0000950170-24-058701-index.htm"},{"fact_type":"material_agreement","fact_key":"52ab4ead495dbc0d33a7c3ea3f30f620a4fc2102","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Investment Agreement","agreement_type":"equity_purchase","counterparty":"Ipsen Biopharmaceuticals, Inc. (USA)","effective_date":"2024-03-29","item_codes_triggered":["1.01"],"value_text":"Ipsen Biopharmaceuticals, Inc. (USA) agreed to purchase 4,827,373 shares of the Company’s common sto"},"claim":"SUTRO BIOPHARMA, INC. entered into Investment Agreement with Ipsen Biopharmaceuticals, Inc. (USA) valued at Ipsen Biopharmaceuticals, Inc. (USA) agreed to purchase 4,827,373 shares of the Company’s common sto (effective 2024-03-29).","evidence_excerpt":"Ipsen Biopharmaceuticals, Inc. (USA) (the “ Investor ”), a fully-owned Affiliate of Ipsen, agreed to purchase 4,827,373 shares of the Company’s common stock (the “ Company Share Issuance ”) for $25 million, at a price per share representing a 17% premium to the volume weighted average price (“ VWAP ”) of the Company’s common stock for the twenty trading day period prior to the parties’ execution of the License Agreement, in accordance with the terms set forth in a certain investment agreement by and between the Company and the Investor dated March 29, 2024 (the “ Investment Agreement ”) and attached as Appendix B to the License Agreement.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-039736","anchor_url":"https://secwatch.observer/filing/0000950170-24-039736#claim-52ab4ead495dbc0d33a7c3ea3f30f620a4fc2102","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024039736/0000950170-24-039736-index.htm"},{"fact_type":"material_agreement","fact_key":"6edbaa214bd6c8bbb63d35a3832e52d4d5e5b194","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Exclusive License Agreement","agreement_type":"license","counterparty":"Ipsen Pharma SAS","effective_date":"2024-03-29","item_codes_triggered":["1.01"],"value_text":"$50 million upfront license fee; $25 million investment for 4,827,373 shares; up to $7 million devel"},"claim":"SUTRO BIOPHARMA, INC. entered into Exclusive License Agreement with Ipsen Pharma SAS valued at $50 million upfront license fee; $25 million investment for 4,827,373 shares; up to $7 million devel (effective 2024-03-29).","evidence_excerpt":"On March 29, 2024, Sutro Biopharma, Inc. (the “ Company ”) and Ipsen Pharma SAS (“ Ipsen ”) entered into an Exclusive License Agreement (the “ License Agreement ”) pursuant to which the Company will license to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-039736","anchor_url":"https://secwatch.observer/filing/0000950170-24-039736#claim-6edbaa214bd6c8bbb63d35a3832e52d4d5e5b194","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024039736/0000950170-24-039736-index.htm"},{"fact_type":"material_agreement","fact_key":"6a286aa3598854d98d48296f0ae23dfba09a1f1e","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"BofA Securities, Inc.","effective_date":"2024-04-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"SUTRO BIOPHARMA, INC. entered into Underwriting Agreement with BofA Securities, Inc. (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell 14,478,764 shares of its common stock (the “Shares”) to the Underwriter (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-040345","anchor_url":"https://secwatch.observer/filing/0000950170-24-040345#claim-6a286aa3598854d98d48296f0ae23dfba09a1f1e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024040345/0000950170-24-040345-index.htm"},{"fact_type":"earnings_release","fact_key":"e959339ffdfda421427a53f0ab48fdad6407caa6","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-03-25T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2023","report_date":"2024-03-25","result_type":"reported_results","revenue_text":"$153.7 million"},"claim":"SUTRO BIOPHARMA, INC. reported the year ended December 31, 2023 results: revenue $153.7 million.","evidence_excerpt":"stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $153.7 million for the year ended December 31, 2023, as compared to $67.8 million for the same period in 2022, with the 2023 amount related principally to the Vaxcyte manufacturing rights","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-035948","anchor_url":"https://secwatch.observer/filing/0000950170-24-035948#claim-e959339ffdfda421427a53f0ab48fdad6407caa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/0000950170-24-035948-index.htm"},{"fact_type":"material_agreement","fact_key":"009d1543cdc0996d4f747f48af3d859ca0117945","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-11-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Manufacturing Rights Agreement","agreement_type":"license","counterparty":"Vaxcyte, Inc.","effective_date":"2023-11-21","item_codes_triggered":["1.01"],"value_text":"$50.0 million"},"claim":"SUTRO BIOPHARMA, INC. entered into Manufacturing Rights Agreement with Vaxcyte, Inc. valued at $50.0 million (effective 2023-11-21).","evidence_excerpt":"(the “Company”) entered into a letter agreement (the “Option Agreement”) with Vaxcyte, Inc. (“Vaxcyte”), under which the Company granted to Vaxcyte (i) authorization to enter into an agreement with an independent alternate contract manufacturing organization (“CMO”) to source cell-free extract solely for the products it licensed from the Company, allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract for use in connection with the exploitation of certain vaccine compositions (the “Option”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-066112","anchor_url":"https://secwatch.observer/filing/0000950170-23-066112#claim-009d1543cdc0996d4f747f48af3d859ca0117945","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023066112/0000950170-23-066112-index.htm"},{"fact_type":"executive_change","fact_key":"aa398b052d","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-11-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-12-01","interim":false,"role":"President and Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Jane Chung was appointed as President and Chief Operating Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On November 21, 2023, Sutro Biopharma, Inc. (the “Company”) announced the appointment of Jane Chung, currently the Company’s Chief Commercial Officer since August 2021, to the position of President and Chief Operating Officer of the Company, effective as of December 1, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-065482","anchor_url":"https://secwatch.observer/filing/0000950170-23-065482#claim-aa398b052d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023065482/0000950170-23-065482-index.htm"},{"fact_type":"earnings_release","fact_key":"655e18d653ac01fb605c8461f44554140d0887c5","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter of 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the third quarter of 2023.","evidence_excerpt":"On November 13, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0000950170-23-063021","anchor_url":"https://secwatch.observer/filing/0000950170-23-063021#claim-655e18d653ac01fb605c8461f44554140d0887c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023063021/0000950170-23-063021-index.htm"},{"fact_type":"earnings_release","fact_key":"a04af4e1bf05c8713a7045e16f33971339bed964","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-08-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter of 2023","report_date":"2023-08-10","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the second quarter of 2023.","evidence_excerpt":"On August 10, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-041404","anchor_url":"https://secwatch.observer/filing/0000950170-23-041404#claim-a04af4e1bf05c8713a7045e16f33971339bed964","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023041404/0000950170-23-041404-index.htm"},{"fact_type":"material_agreement","fact_key":"c4b2e99ee2f9c210b684c34be08ddfd3bd20f535","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"asset_purchase","counterparty":"affiliate of Blackstone Life Sciences","effective_date":"2023-06-21","item_codes_triggered":["1.01"],"value_text":"$140.0 million"},"claim":"SUTRO BIOPHARMA, INC. entered into Purchase Agreement with affiliate of Blackstone Life Sciences valued at $140.0 million (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, Sutro Biopharma, Inc. (the “ Company ”) entered into a purchase and sale agreement (the “ Purchase Agreement ”) with an affiliate of Blackstone Life Sciences (“ Blackstone ”, and together with the Company, the “ Parties ”), pursuant to which the Company sold to Blackstone its 4% royalty, or revenue interest, in the potential future net sales of Vaxcyte Inc.’s (“ Vaxcyte ”) products, including VAX-24 (the “ Purchased Interest ”) under that certain Amended and Restated SutroVax Agreement, dated October 12, 2015, by and between the Company and Vaxcyte, as amended (the “ License Agreement ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-029731","anchor_url":"https://secwatch.observer/filing/0000950170-23-029731#claim-c4b2e99ee2f9c210b684c34be08ddfd3bd20f535","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023029731/0000950170-23-029731-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c285d2430170caad419d3cbb8fb825e5c5235d1a","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions","proposal_type":"charter_amendment","results":[{"broker_non_votes":"4,402,194","subject":null,"votes_abstain":"17,080","votes_against":"5,507,942","votes_for":"43,016,509","votes_withheld":null}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions at the 2023-06-08 meeting.","evidence_excerpt":"4. Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions: Shares For Shares Against Shares Abstaining Broker Non-Votes 43,016,509 5,507,942 17,080 4,402,194","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-027975","anchor_url":"https://secwatch.observer/filing/0000950170-23-027975#claim-c285d2430170caad419d3cbb8fb825e5c5235d1a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0751e78180a89ac3afb2209d0608d38be583db0d","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,402,194","subject":null,"votes_abstain":"17,368","votes_against":"9,377,370","votes_for":"39,146,793","votes_withheld":null}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-08 meeting.","evidence_excerpt":"3. Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 39,146,793 9,377,370 17,368 4,402,194","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-027975","anchor_url":"https://secwatch.observer/filing/0000950170-23-027975#claim-0751e78180a89ac3afb2209d0608d38be583db0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4e32a3b4c9f0a1570448db4baac44b562e8b9d62","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"13,576","votes_against":"42,108","votes_for":"52,888,041","votes_withheld":null}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.","evidence_excerpt":"2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Abstaining Broker Non-Votes 52,888,041 42,108 13,576 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-027975","anchor_url":"https://secwatch.observer/filing/0000950170-23-027975#claim-4e32a3b4c9f0a1570448db4baac44b562e8b9d62","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm"},{"fact_type":"shareholder_vote","fact_key":"331dc632644ec117755f1a41f54ab84e8e262110","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Election of three Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,402,194","subject":"William J. Newell","votes_abstain":null,"votes_against":null,"votes_for":"39,690,178","votes_withheld":"8,851,353"},{"broker_non_votes":"4,402,194","subject":"Connie Matsui","votes_abstain":null,"votes_against":null,"votes_for":"29,080,240","votes_withheld":"19,461,291"},{"broker_non_votes":"4,402,194","subject":"James Panek","votes_abstain":null,"votes_against":null,"votes_for":"31,714,990","votes_withheld":"16,826,541"}]},"claim":"SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2023-06-08 meeting.","evidence_excerpt":"On June 8, 2023, the Company held its 2023 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of three Class II directors, identified in the table below, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes William J. Newell 39,690,178 8,851,353 4,402,194 Connie Matsui 29,080,240 19,461,291 4,402,194 James Panek 31,714,990 16,826,541 4,402,194","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-027975","anchor_url":"https://secwatch.observer/filing/0000950170-23-027975#claim-331dc632644ec117755f1a41f54ab84e8e262110","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm"},{"fact_type":"earnings_release","fact_key":"d2283565af456f5a031e9a82fb689f9b487f6db1","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2023","report_date":"2023-05-15","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-23-021973","anchor_url":"https://secwatch.observer/filing/0000950170-23-021973#claim-d2283565af456f5a031e9a82fb689f9b487f6db1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023021973/0000950170-23-021973-index.htm"},{"fact_type":"executive_change","fact_key":"0f0f1e05a6","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-04-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-05-31","interim":false,"role":"President of Research and Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Trevor Hallam resigned as President of Research and Chief Scientific Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On April 24, 2023, Dr. Trevor Hallam notified Sutro Biopharma, Inc. (the “ Company ”) that he will resign from his role as President of Research and Chief Scientific Officer of the Company, effective May 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-015323","anchor_url":"https://secwatch.observer/filing/0000950170-23-015323#claim-0f0f1e05a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023015323/0000950170-23-015323-index.htm"},{"fact_type":"executive_change","fact_key":"234cb90897","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-04-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-04-10","interim":false,"role":"Class III Director and Chair of the Audit Committee","role_category":"director","successor_name":null,"successor_named":false},"claim":"Shalini Sharp resigned as Class III Director and Chair of the Audit Committee at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On April 10, 2023, Shalini Sharp notified the Board of Directors (the “Board”) of Sutro Biopharma, Inc. (the “Company”) of her resignation as a Class III director and as the Chair of the Audit Committee of the Board (the “Audit Committee”), effective immediately (the “Resignation”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-23-012879","anchor_url":"https://secwatch.observer/filing/0000950170-23-012879#claim-234cb90897","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023012879/0000950170-23-012879-index.htm"},{"fact_type":"earnings_release","fact_key":"731fe9be16bde417557352b4d0ad9180d2f45e8e","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year 2022","report_date":"2023-03-30","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for the full year 2022.","evidence_excerpt":"On March 30, 2023, Sutro Biopharma, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-010978","anchor_url":"https://secwatch.observer/filing/0000950170-23-010978#claim-731fe9be16bde417557352b4d0ad9180d2f45e8e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm"},{"fact_type":"governance_change","fact_key":"9ab748aed4d9a3cbbea05416d50713f65589c3f2","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-02-24T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-02-24","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to conform to DGCL amendments and universal proxy rules, including updates to stockholder meeting procedures, advance notice provisions, and emergency bylaws."},"claim":"SUTRO BIOPHARMA, INC.: Amended and restated bylaws to conform to DGCL amendments and universal proxy rules, including updates to stockholder meeting procedures, advance notice provisions, and emergency bylaws (effective 2023-02-24).","evidence_excerpt":"On February 24, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the restated bylaws of Sutro Biopharma, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-23-004373","anchor_url":"https://secwatch.observer/filing/0000950170-23-004373#claim-9ab748aed4d9a3cbbea05416d50713f65589c3f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023004373/0000950170-23-004373-index.htm"},{"fact_type":"material_agreement","fact_key":"dc2d75e6b22e84fafe47962f40a09c1935d4b5ef","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-12-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Letter Agreement","agreement_type":"license","counterparty":"Vaxcyte, Inc.","effective_date":"2022-12-19","item_codes_triggered":["1.01"],"value_text":"Upfront payment of $22.5 million ($7.5 million in shares and $15 million in cash) and potential mile"},"claim":"SUTRO BIOPHARMA, INC. entered into Letter Agreement with Vaxcyte, Inc. valued at Upfront payment of $22.5 million ($7.5 million in shares and $15 million in cash) and potential mile (effective 2022-12-19).","evidence_excerpt":"On December 19, 2022, Sutro Biopharma, Inc. (the “ Company ”) entered into a letter agreement (the “ Agreement ”) with Vaxcyte, Inc. (“ Vaxcyte ”) under which the Company granted to Vaxcyte (i) authorization to enter into an agreement with an independent alternate contract manufacturing organization (“ CMO ”) to source cell-free extract solely for the products it licensed from the Company, allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO, and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract for use in connection with the exploitation of certain vaccine compositions (the “ Option ”). The Option is exercisable for five years following the effective date of the Agreement (the “ Option Period ”), subject to potential acceleration in the event of a change of control of","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-22-026823","anchor_url":"https://secwatch.observer/filing/0000950170-22-026823#claim-dc2d75e6b22e84fafe47962f40a09c1935d4b5ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022026823/0000950170-22-026823-index.htm"},{"fact_type":"earnings_release","fact_key":"1fdf764888d43e079041ed121ef4ac894b6c19e8","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":null},"claim":"SUTRO BIOPHARMA, INC. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-22-023274","anchor_url":"https://secwatch.observer/filing/0000950170-22-023274#claim-1fdf764888d43e079041ed121ef4ac894b6c19e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm"},{"fact_type":"executive_change","fact_key":"4f2cef3914","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-10-24T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-11-04","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Arturo Molina resigned as Chief Medical Officer at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On October 18, 2022, Dr. Arturo Molina notified Sutro Biopharma, Inc. (the “ Company ”) that he will resign from his role as Chief Medical Officer of the Company, effective November 4, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-22-019872","anchor_url":"https://secwatch.observer/filing/0000950170-22-019872#claim-4f2cef3914","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022019872/0000950170-22-019872-index.htm"},{"fact_type":"executive_change","fact_key":"ef808f71ae","cik":1382101,"ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2021-11-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-11-19","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Heidi Hunter was appointed as Class I director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On November 12, 2021, the board of directors (the “ Board ”) of Sutro Biopharma, Inc. (the “ Company ”) appointed Heidi Hunter, as a Class I director and member of the Audit Committee and Science and Technology Committee, effective as of November 19, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001564590-21-057374","anchor_url":"https://secwatch.observer/filing/0001564590-21-057374#claim-ef808f71ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1382101/000156459021057374/0001564590-21-057374-index.htm"}]}